Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Biktarvy is a prescription three-drug HIV-1 medicine containing bictegravir, emtricitabine, and tenofovir alafenamide. It is used as a complete regimen in adults and pediatric patients weighing at least 14 kg who meet labeled treatment and resistance criteria. It comes in two tablet strengths, with the dose based mainly on body weight.
read more about biktarvy ...Bictegravir blocks HIV-1 integrase and prevents viral DNA from being inserted into human cell DNA. Emtricitabine and tenofovir alafenamide form active metabolites that inhibit HIV-1 reverse transcriptase and stop viral DNA chain growth. Acting at different stages of replication suppresses production of new HIV-1 particles.
Biktarvy is approved for adults and children weighing at least 14 kg with HIV-1. The current label covers people with no prior antiretroviral treatment, selected people who previously received antiretroviral therapy and are not virologically suppressed without specified resistance substitutions, and virologically suppressed patients switching from a stable regimen when resistance criteria are met.
Adults and children weighing at least 25 kg take one tablet containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide once daily. Children weighing 14 kg to under 25 kg take the lower-strength tablet once daily. Biktarvy is taken with or without food.
Biktarvy carries a boxed warning for severe acute hepatitis B exacerbation after treatment stops in people with HIV-1 and hepatitis B coinfection. Other concerns include kidney impairment, lactic acidosis, severe liver enlargement with fat accumulation, immune reconstitution syndrome, and clinically significant drug interactions. Dofetilide and rifampin are contraindicated.
Biktarvy contains three antiretroviral medicines, bictegravir, emtricitabine, and tenofovir alafenamide.
Biktarvy is taken once daily. The tablet strength depends mainly on body weight.
Yes. Biktarvy tablets are taken with or without food.
Emtricitabine and tenofovir have activity against hepatitis B, and stopping Biktarvy can trigger severe hepatitis B worsening in coinfected patients.
BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) Prescribing Information. https://www.biktarvyhcp.com/~/media/Affinity/Biktarvyhcp/pdfs/biktarvy_pi.pdf. Date Accessed September 16, 2026.
Bictegravir, Emtricitabine, and Tenofovir Alafenamide. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a618012.html. Date Accessed September 16, 2026.
DailyMed - BIKTARVY (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=664cb8f0-1f65-441b-b0d9-ba3d798be309. Date Accessed September 16, 2026.
FDA Label - BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210251Orig1s026lbl.pdf. Date Accessed September 16, 2026.
FDA-Approved HIV Medicines. HIVinfo. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines. Date Accessed September 16, 2026.